Advocates accuse Drug Enforcement Administration of blocking the reclassification of cannabis as a Schedule III drug under the Controlled Substances Act.
Attorneys for a cannabis company and advocacy group that are set to testify in the Drug Enforcement Administration’s (DEA) marijuana rescheduling hearing process beginning this month say new evidence ...
As we rev up in 2025, here’s what I see as the main issues/events to watch (and maybe act on) in the industry: For years, “cannabis litigation” didn’t exist because business was conducted in the ...